

# *In Silico* Study of Dibenzylidene Cyclohexanone-Based Curcumin Analogs as Potential Inhibitors of Breast Cancer Receptor Proteins



Ranti Kamila Habibie<sup>1</sup>  and Ritmaleni<sup>2,3,\*</sup> 

<sup>1</sup>Pharmaceutical Sciences, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Sleman, Yogyakarta 55281, Indonesia

<sup>2</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Sleman, Yogyakarta 55281, Indonesia

<sup>3</sup>Curcumin Research Center, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Sleman, Yogyakarta 55281, Indonesia

## Abstract:

**Background:** Cancer is one of the leading causes of death worldwide, accounting for approximately 10 million deaths annually. The most prevalent type of cancer in women is breast cancer, and there are not any prospective vaccinations available for the treatment of this disease.

**Objective:** This study aimed to identify potent substances derived from natural products, such as curcumin analogs, which are crucial for enriching drug discovery, particularly in the prevention of breast cancer.

**Methods:** This study utilized twelve novel curcumin analogs, specifically dibenzylidene-cyclohexanones, to predict their biological activity against breast cancer. Based on Lipinski's rule of five, selected compounds were screened using ADMETlab 3.0 to assess their drug-likeness properties. Then, the selected compounds were subsequently subjected to pharmacophore modeling using LigandScout, followed by molecular docking studies with the human estrogen receptor alpha (ER $\alpha$ ; PDB ID: 2IOG) using AutoDock. Curcumin and tamoxifen were included as reference compounds for comparison.

**Results:** Based on the research conducted, all of the curcumin analogs met the criteria of Lipinski's rule of five, except compound **12**. Compound **4** demonstrated the best potential as an anticancer agent against ER $\alpha$ , with a pharmacophore fit-score of 36.87 based on pharmacophore modeling and binding energy of -11.10 kcal, which was higher than tamoxifen (-10.45 kcal/mol) and curcumin (-9.18 kcal/mol) based on a molecular docking study.

**Conclusion:** Exploring curcumin analogs as potential anti-breast cancer agents is crucial for drug discovery and development. This study suggests that curcumin analog compound **4** can act as a potent inhibitor against ER $\alpha$ . However, further *in vitro* studies are required to confirm the efficacy of this compound.

**Keywords:** Curcumin analogs, Anticancer, Breast cancer, Molecular docking, Virtual screening.

© 2025 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\* Address correspondence to this author at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia, and Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Sleman, Yogyakarta 55281, Indonesia; Tel: +62 812-2738-6919; E-mail: ritmaleni@ugm.ac.id

Cite as: Habibie R, Ritmaleni. *In Silico* Study of Dibenzylidene Cyclohexanone-Based Curcumin Analogs as Potential Inhibitors of Breast Cancer Receptor Proteins. Open Bioinform J, 2025; 18: e18750362383003. <http://dx.doi.org/10.2174/0118750362383003250527080758>



Received: January 23, 2025

Revised: April 14, 2025

Accepted: May 02, 2025

Published: June 02, 2025



Send Orders for Reprints to [reprints@benthamscience.net](mailto:reprints@benthamscience.net)

## 1. INTRODUCTION

Breast cancer, as defined by the World Health Organization (WHO), is a disease characterized by the uncontrolled growth of abnormal breast cells that can form tumors. If left untreated, tumors have the potential to spread throughout the body and become fatal.

Breast cancer cells first multiply in the milk ducts and/or the milk-producing lobules of the breast. In 2022, 2.3 million women were diagnosed with breast cancer, and 670,000 people died from the disease worldwide. Breast cancer can affect women at any age after puberty, with its incidence increasing as women grow older [1].

The degree to which the cancer has progressed to lymph nodes or other bodily areas will depend on its subtype. There are many treatments available for breast cancer. Breast cancer subtypes based on the expression of the hormone receptors are categorized into four categories: human epidermal growth factor receptor-2 positive (HER-2+), progesterone receptor positive (PR+), estrogen receptor-positive (ER+), and those that lack expression of all three receptors, known as triple-negative breast cancer (TNBC), which is more aggressive than other subtypes [1, 2].

Estrogen receptor (ER) and progesterone receptor (PR) are hormones that are essential for regulating key physiological processes, such as sexual maturation (including breast development), pregnancy, postpartum, and menopause. However, normal breast cells can become cancerous when DNA damage occurs, leading to rapid growth and uncontrolled spread, often influenced by related hormones [3]. Alpha ( $\alpha$ ) and beta ( $\beta$ ) estrogen receptors are encoded by two genes, ESR1 and ESR2, respectively [4]. Examples of endocrine (hormone) therapies that are effective in treating malignancies expressing ER and/or PR include tamoxifen and aromatase inhibitors. Chemotherapy is required for "hormone receptor negative" cancers that do not express either ER or PR [1].

Much research has been carried out to find and develop drugs that can inhibit this highly aggressive cancer [5-8]. One of the most challenging obstacles in treating breast cancer, which eventually results in death, is multidrug resistance. Therefore, an in-depth understanding and analysis of the molecular basis of cancer resistance is required, and the development of new effective drugs is urgently needed [9].

Natural materials have been used as a source of medicine for many years. Today, approximately half of all pharmaceutical drugs are still derived from natural sources. These products are usually isolated from plants, marine flora, and microorganisms. Their therapeutic potential can be enhanced through structural modification [10, 11].

Curcumin is a major bioactive compound found in rhizomes and has attracted significant attention from researchers due to its diverse biological activities. It has shown potential benefits in conditions, such as cardio-


vascular diseases, diabetes mellitus, *etc* [11, 12]. Previous studies reported that curcumin has the potential to be an anti-breast cancer agent because it affects the number of phenotypes through mechanisms of action, such as (a) P-glycoprotein activity inhibition and drug resistance reduction, (b) cell cycle induction, (c) ferroptosis and apoptosis initiation, and (d) control of the epithelial-mesenchymal transition (EMT) [13, 14].

Other reports demonstrated that curcumin exhibits its anticancer properties *via* a complex molecular signaling network that includes those related to HER-2, ER, and proliferative pathways. In addition, experimental studies have reported that curcumin regulates genes and microRNAs linked to cell phase and apoptosis in breast cancer cells [15]. However, curcumin is known to have a poor pharmacokinetic profile, and its systemic bioavailability is low due to limited absorption, rapid metabolism, and rapid excretion. One way to slow down the metabolism of curcumin is to explore new curcumin-derived compounds with lower toxicity yet increased effectiveness [16].

Structural modification of curcumin is expected to serve as a next-generation drug candidate for cancer therapy. Several research works have been carried out to explore the effects of curcumin and its analogs as cancer therapy, especially in breast cancer. Several curcumin analogs have been synthesized and tested for their anticancer activity using *in-vitro* methods in MCF-7 cells, and it was found that some curcumin analogs exhibit toxicity even at small concentrations [8, 17].

A previous study conducted by Shen *et al.* (2020) reported that curcumin analog with mono-carbonyl (acetone) B14 has antitumor activity and potent selectivity for MCF-7 and MDA-M-231 cells with  $IC_{50}$  values of 8.84 and 8.33  $\mu\text{mol/L}$ , respectively. Its  $IC_{50}$  value for MCF-10A breast epithelial cells was 34.96  $\mu\text{mol/L}$ . Moreover, B14 demonstrated better bioavailability compared to curcumin [18]. Furthermore, monocarbonyl curcumin analogues have been shown to have enhanced intestinal permeability and water solubility, as well as good chemical and metabolic stability linked to improved bioavailability [19].

Based on previous studies and the global prevalence of breast cancer, curcumin analogs, particularly monocarbonyl curcumin analogs, show promising potential as anti-breast cancer agents. The findings of this study can be a source of updated information for researchers on the topic of curcumin analogs as potential breast cancer agents. In a previous study, the curcumin analogs with dibenzylidene-cyclohexanones (Fig. 1) [17, 18] were tested for their antioxidant activity. In this study, we aim to evaluate the pharmacokinetic and ADMET profiles of these compounds through virtual screening, as well as assess their interaction with human estrogen receptor alpha ( $ER\alpha$ ), a key breast cancer receptor, using pharmacophore modeling and molecular docking in an *in silico* approach. This study is preliminary research, which is expected to continue with synthesized and laboratory tests.



**Fig (1).** Structure template for dibenzylidene-cyclohexanones.

## 2. MATERIALS AND METHODS

### 2.1. Analysis of Drug-Likeness Properties

The evaluation of drug-likeness properties was performed based on Lipinski's rule of five (molecular weight (MW)  $\leq$  500 Daltons,  $\log P \leq 5$ , hydrogen bond acceptors (HBA)  $\leq 10$ , and hydrogen bond donors (HBD)  $\leq 5$ ) [20] using ADMETlab 3.0 (<https://admetlab3.scbdd.com/>) [21]. Table 1 presents the tested ligands with their structures shown in Fig. (1) as a template. This study used canonical SMILES generated by MarvinSketch after drawing the structures of the compounds.

### 2.2. Pharmacophore Modeling

The pharmacophore model was carried out using LigandScout v4.4.1 (licensed by Padjajaran University). LigandScout employs the Espresso algorithm, which involves multiple stages, such as clustering and conformation generation. The LigandScout algorithm creates a pharmacophore on each training molecule and then aligns the test molecule using this pharmacophore [22]. Therefore, pharmacophore modeling started with model validation, which is crucial for virtual screening as it helps predict the possible pharmacophore activities at the receptor. In this process, a 1:4 ratio of active compounds to decoy compounds obtained from the DUD-E database (<https://dude.docking.org/>) was used. This process ensures the selection of models with sufficient accuracy [23].

The pharmacophore validation process yielded a model based on the structure of the active compound, which was

subsequently used to screen curcumin analog test compounds. The model was based on the receiver operating characteristic (ROC) curve, true positive (TP), and false positive (FP). The ROC curve illustrates the model's ability to distinguish between active and inactive substances, and this performance is measured by the area under the ROC curve (AUC) [22]. An AUC value close to 0 indicates a poor classifier, as the model incorrectly ranks decoys (compounds that should be inactive) higher than active compounds. Conversely, an AUC value close to 1 indicates an excellent classifier, correctly prioritizing active compounds over decoys. In addition, other statistical parameters like goodness-of-hit score (GH), enrichment factor (EF), and accuracy (ACC) will determine the performance of the model [23, 24].

The 3D structures of these compounds were constructed using the ChemDraw application. They were then combined using Discovery Studio and saved in .sdf format. The hit compounds were selected based on their pharmacophore fit score values.

### 2.3. Molecular Docking

#### 2.3.1. Selection and Retrieval of Receptors

Literature was searched for possible targets for anti-cancer treatments. The three-dimensional structure (in PDB format) of each of the selected receptors was retrieved from the RCSB protein data bank (PDB) (<https://www.rcsb.org/>) using PDB ID 2IOG (human estrogen receptor alpha ligand-binding domain in complex with compound 11F) [25].

**Table 1.** List of curcumin analogs.

Compounds	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>
Compound 1	-H	-Br	-OCH <sub>3</sub>	-H	-H
Compound 2	-COOH	-H	-H	-H	-H
Compound 3	-Cl	-H	-H	-H	-F
Compound 4	-Cl	-H	-Cl	-H	-H
Compound 5	-OH	-OCH <sub>2</sub> CH <sub>3</sub>	-H	-H	-H
Compound 6	-H	-OCH <sub>2</sub> CH <sub>3</sub>	-OH	-H	-H
Compound 7	-H	-H	-H	-NO <sub>2</sub>	-H
Compound 8	-H	-COH	-H	-H	-H
Compound 9	-OCH <sub>3</sub>	-H	-H	-OCH <sub>3</sub>	-H
Compound 10	-OCH <sub>3</sub>	-H	-H	-H	-H
Compound 11	-H	-OH	-H	-H	-H
Compound 12	-H	-Br	-OH	-Br	-H

### 2.3.2. Retrieval of Ligands and Screening

The structures of all curcumin analogs were obtained from the literature [17, 18] and used in molecular docking studies to investigate their interactions with the target protein. The reference and control compounds were retrieved from the PubChem compound database (<https://pubchem.ncbi.nlm.nih.gov/>) using PubChem CID (Curcumin: 969516, Tamoxifen: 2733526) [26]. Curcumin analogs were drawn and optimized by energy minimization using the Merck molecular force field (MMFF94) on the MarvinSketch application (<https://www.chemaxon.com>).

### 2.3.3. Molecular Docking Studies

AutoDock v4.2.6 software (AutoDock 4.2, Scripps Research, La Jolla, CA, USA, <https://autodock.scripps.edu/download-autodock4/>, accessed on 20<sup>th</sup> December, 2023) was used in this study for molecular docking. Validation analysis of the native ligand was carried out to determine the Root Mean Standard Deviation (RMSD) value and grid box. RMSD showed 0.82 Å, and the grid box dimensions were adjusted on the X, Y, and Z coordinates to 50 × 44 × 46. The grid center was 31.767, -0.942, and 24.202, respectively, in the active site of ER $\alpha$ . AutoGrid was used to construct a 3D grid around the receptor's target binding location to make docking calculations easier [27]. The binding energy and inhibition constant of the interaction between the ligands and targets were estimated using the Lamarckian genetic algorithm (with a maximum of 100 conformers evaluated for each chemical to obtain optimal conformation). The remaining parameters were left as default for the molecular docking study.

AutoDock employs the Lamarckian Genetic Algorithm (LGA). This algorithm is used to determine the optimal docking position between the ligand and the protein, which then generates the function's empirical binding free energy value. This algorithm allows the ligand to move flexibly. Molecular mechanics components, including dispersion or repulsion, hydrogen bonding, electrostatic interactions, and covalent geometry optimization, constitute the first four terms in the algorithm's molecular free energy calculation. The final terms account for internal torsional strain, global rotation and translation, desolvation upon binding, and hydrophobic interactions. A good ligand conformation is typically associated with a lower binding free energy [28].

After the validation analysis and determining the algorithm, molecular docking was carried out between the curcumin analogs and the protein. All of the steps were similar to the validation analysis, including the dimensions of the grid box. The only difference was that we used our energy-minimized ligand for the analysis. The results showed the binding energy and interactions between the ligands and the protein, demonstrating their potential compatibility as anticancer agents.

## 3. RESULTS AND DISCUSSION

The curcumin analogs utilized in this study were

dibenzylidene-cyclohexanone derivatives, which were successfully synthesized in a previous study and reported to have antioxidant activity better than tocopherol [17, 18]. Antioxidants help to protect cells from damage caused by free radicals or oxidative stress, which are one of the factors that can cause various diseases, including cancer [29]. It has been found that antioxidants like vitamin C (ascorbic acid), vitamin E (tocopherol), and beta-carotene have potential anti-cancer effects [30]. Therefore, our study investigated the potential of these curcumin analogs as anticancer agents, especially for the treatment of breast cancer.

The backbone structure (Fig. 1) with various substituents (Table 1) was designed using the Marvin Sketch application, generating 2D structures and canonical SMILES for each compound. These were used for virtual pharmacokinetic screening—including drug-likeness evaluation, pharmacophore modeling, and molecular docking. The primary target protein is human estrogen receptor alpha (ER $\alpha$ ; PDB ID: 2IOG), which plays a key role in breast cancer.

### 3.1. Analysis of Drug-Likeness Properties

Drug-likeness properties and ADMET prediction were assessed using ADMETlab 3.0 [21]. Properties like molecular weight, hydrogen bond acceptor, hydrogen bond donor, and LogP were identified using Lipinski's rule of five, as mentioned in Table 2. The molecule should have a molecular weight of  $\leq 500$ , a partition coefficient (LogP) of  $\leq 5$ , hydrogen bond donors of  $\leq 5$ , and hydrogen bond acceptors of  $\leq 10$ , respectively, to adsorb well following Lipinski's rule of five [20]. The LogP is a logarithm of the octanol-water partition coefficient, which measures a compound's lipophilicity or its tendency to dissolve in lipids (like octanol) compared to water [31].

Oral bioavailability is believed to be significantly influenced by each of these characteristics, as well as molecular flexibility [32]. If the compound has two or more violations of Lipinski's rule of five, its absorption in the intestine will be low. All curcumin analogs met Lipinski's rule of five, except compound 12. Compound 12 did not meet the criteria in terms of molecular weight and LogP, indicating its poor oral bioavailability based on virtual screening.


### 3.2. Pharmacophore Modeling

Validation of the pharmacophore modeling method was carried out to confirm the ability of the pharmacophore model to distinguish the structures of active and inactive compounds [33]. Model nine showed the best performance with AUC values of 1.00, 1.00, and 0.85 at thresholds 1.5, 10, and 100%, respectively, along with 72 true positives (TP) and 32 false positives (FP). These values are very good as they are close to 1. The ROC plot is shown in Fig. (2A). The pharmacophore features are presented in Fig. (2B). Three features were created in the model: one hydrophobic feature (AR) depicted by a yellowish sphere, one hydrogen bond donor (HBD), and one hydrogen bond acceptors (HBA) seen with a red-green sphere shape.

**Table 2. Drug-likeness properties of curcumin analogs.**


Compounds	Criteria	Drug-likeness			
		MW* ( $\leq 500$ )	HBA* ( $\leq 10$ )	HBD* ( $\leq 5$ )	LogP* ( $\leq 5$ )
Curcumin	Yes	368.13	6	2	2.374
Compound 1	Yes	489.98	3	0	5.01
Compound 2	Yes	378.35	5	2	3.93
Compound 3	Yes	356.43	1	0	5.03
Compound 4	Yes	409.98	1	0	6.32
Compound 5	Yes	394.18	5	2	4.07
Compound 6	Yes	394.18	5	2	3.82
Compound 7	Yes	364.11	7	0	4.40
Compound 8	Yes	330.13	3	0	3.88
Compound 9	Yes	394.18	5	0	4.65
Compound 10	Yes	334.16	3	0	4.75
Compound 11	Yes	306.13	3	2	3.63
Compound 12	No	617.77	3	2	5.514
Tamoxifen	Yes	371.22	2	0	6.311

**Note:**\*MW: Molecular weight; HBA: Hydrogen bond acceptor; HBD: Hydrogen bond donor; LogP: Coefficient partitions.



1 - Specificity (% retrieved decoys)

(A)






(B)

**Fig (2).** (A) ROC plot of the pharmacophore model and (B) Visualization of ligand-based pharmacophore features.

This pharmacophore model tested curcumin analogs mapped according to the same pharmacophore. From this study, it can be predicted that if the structures have the same pharmacophore, they will have the same biological properties [34]. The hit compounds are listed in Table 3, indicating that two out of twelve had the highest pharmacophore fit score. The pharmacophore fit-score

values evaluated the degree of overlap between the pharmacophore features and the compound's chemical functions [23]. The pharmacophore study identified two curcumin analogs, compounds 4 and 11, that have pharmacophore fit-score values similar to the model and have the same pharmacophore as the active compound (training set).

**Table 3. Pharmacophore model results: Two-dimensional and three-dimensional projections of the pharmacophore model and hit compounds.**

Compounds	Pharmacophore Fit-Score	Mapping in 2D and 3D
Model (active compound)	46.87	
Compound 4	36.87	
Compound 11	36.65	

**Note:** The pharmacophore features are hydrophobic features (yellowish sphere) and hydrogen bond acceptor-donor (red-green sphere).

### 3.3. Molecular Docking

Molecular docking studies were conducted to predict the binding mode, affinity, binding free energy ( $\Delta G$ ), and interaction between a small molecule and protein target



receptors [35]. They were carried out using AutoDock between ten curcumin analogs, curcumin, and tamoxifen against the ER $\alpha$  enzyme. Before molecular docking with the tested compounds, the validation method was perfor-

med first to determine the grid box and Root Mean Square Deviation (RMSD). RMSD was used to compare the docking orientation between the corresponding co-crystallized pose of the same ligand molecule. Three solutions were identified based on the RMSD value: (a) good solutions when the RMSD was less than 2.0, (b) acceptable solutions when the RMSD was between 2.0 and 3.0, and (c) bad solutions when the RMSD was greater than 3.0 [36].




The validation method result showed a good solution with an RMSD value of 0.82 Å. The interaction between

the native ligand and the protein was based on literature data from the RCSB PDB, highlighting Asp351 as a key amino acid residue in the catalytic site. This residue was also identified from studies on the interactions of raloxifene and bazedoxifene with human ER $\alpha$  [25]. Subsequently, molecular docking of curcumin analogs was performed using the same validated method. In this study, curcumin was used as a lead compound, and tamoxifen was used for comparison. The binding energy and inhibition constant ( $K_i$ ) of curcumin analogs are presented in Table 4.

**Table 4. Molecular docking results from curcumin analogs and 2D interaction between amino acids and ligands.**




Compounds	Binding Energy (kcal/mol)	Inhibition Constant ( $K_i$ ) (nM)	2D Interaction (Protein-ligand)
Native ligand (Compound <b>11F</b> )	-14.51	0.02	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Salt Bridge</li> <li>Conventional Hydrogen Bond</li> <li>Pi-Sulfur</li> <li>Pi-Pi Stacked</li> <li>Pi-Pi T-shaped</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>
Curcumin	-9.18	186.65	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Conventional Hydrogen Bond</li> <li>Carbon Hydrogen Bond</li> <li>Pi-Sigma</li> <li>Pi-Pi T-shaped</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>

(Table 6) contd.....




Compounds	Binding Energy (kcal/mol)	Inhibition Constant (Ki) (nM)	2D Interaction (Protein-ligand)
Compound 1	-10.76	12.87	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>Carbon Hydrogen Bond</li> <li>Pi-Anion</li> <li>Pi-Sigma</li> <li>Pi-Sulfur</li> <li>Pi-Pi Stacked</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>
Compound 2	-9.22	174.44	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Attractive Charge</li> <li>Conventional Hydrogen Bond</li> <li>Pi-Sulfur</li> <li>Pi-Pi T-shaped</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>
Compound 3	-10.09	40.08	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Carbon Hydrogen Bond</li> <li>Halogen (Fluorine)</li> <li>Pi-Sulfur</li> <li>Pi-Pi Stacked</li> <li>Pi-Pi T-shaped</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>






(Table 6) contd....

Compounds	Binding Energy (kcal/mol)	Inhibition Constant (K <sub>i</sub> ) (nM)	2D Interaction (Protein-ligand)
Compound 4	-11.10	7.36	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Pi-Anion</li> <li>Pi-Sulfur</li> <li>Pi-Pi Stacked</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>
Compound 5	-9.29	155.92	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Conventional Hydrogen Bond</li> <li>Carbon Hydrogen Bond</li> <li>Pi-Anion</li> <li>Pi-Sulfur</li> <li>Pi-Pi Stacked</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>
Compound 6	-10.24	31.38	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Conventional Hydrogen Bond</li> <li>Pi-Sulfur</li> <li>Pi-Pi Stacked</li> <li>Pi-Pi T-shaped</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>

(Table 6) contd....

Compounds	Binding Energy (kcal/mol)	Inhibition Constant (Ki) (nM)	2D Interaction (Protein-ligand)
Compound 7	-10.24	31.12	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li><span style="color: green;">■</span> van der Waals</li> <li><span style="color: red;">■</span> Conventional Hydrogen Bond</li> <li><span style="color: orange;">■</span> Pi-Sulfur</li> <li><span style="color: magenta;">■</span> Pi-Pi T-shaped</li> <li><span style="color: pink;">■</span> Alkyl</li> <li><span style="color: purple;">■</span> Pi-Alkyl</li> </ul>
Compound 8	-10.17	34.88	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li><span style="color: green;">■</span> van der Waals</li> <li><span style="color: red;">■</span> Conventional Hydrogen Bond</li> <li><span style="color: lightgreen;">■</span> Carbon Hydrogen Bond</li> <li><span style="color: orange;">■</span> Pi-Sulfur</li> <li><span style="color: magenta;">■</span> Pi-Pi T-shaped</li> <li><span style="color: pink;">■</span> Alkyl</li> <li><span style="color: purple;">■</span> Pi-Alkyl</li> </ul>
Compound 9	-9.80	65.82	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li><span style="color: green;">■</span> van der Waals</li> <li><span style="color: red;">■</span> Conventional Hydrogen Bond</li> <li><span style="color: orange;">■</span> Pi-Anion</li> <li><span style="color: yellow;">■</span> Pi-Sulfur</li> <li><span style="color: magenta;">■</span> Pi-Pi Stacked</li> <li><span style="color: pink;">■</span> Alkyl</li> <li><span style="color: purple;">■</span> Pi-Alkyl</li> </ul>

(Table 6) contd....

Compounds	Binding Energy (kcal/mol)	Inhibition Constant (K <sub>i</sub> ) (nM)	2D Interaction (Protein-ligand)
Compound 10	-9.77	68.67	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Carbon Hydrogen Bond</li> <li>Alkyl</li> <li>Pi-Alkyl</li> <li>Pi-Pi T-shaped</li> </ul>
Compound 11	-9.97	49.07	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>van der Waals</li> <li>Conventional Hydrogen Bond</li> <li>Alkyl</li> <li>Pi-Alkyl</li> <li>Pi-Pi T-shaped</li> </ul>
Compound 12	-12.06	1.45	 <p><b>Interactions</b></p> <ul style="list-style-type: none"> <li>Halogen (Cl, Br, I)</li> <li>Pi-Anion</li> <li>Pi-Pi Stacked</li> <li>Alkyl</li> <li>Pi-Alkyl</li> </ul>

(Table 6) contd.....

Compounds	Binding Energy (kcal/mol)	Inhibition Constant (Ki) (nM)	2D Interaction (Protein-ligand)
Tamoxifen	-10.45	21.87	

**Note:** The colors below the structures indicate the type of interactions for each compound.

Tamoxifen is a common treatment for breast cancer; it works by reducing estrogen activity in certain tissues. Similar to many cancer drugs, it has various adverse effects. Hot flashes, irregular periods, vaginal discharge, peripheral edema, hypertension, mood swings, discomfort, depression, skin rashes and changes, weakness, nausea and vomiting, arthritis, arthralgia, lymphedema, and pharyngitis are some of the other frequent side effects caused by tamoxifen [37]. There is a need to search for drugs that have lower side effects to overcome the increasing drug resistance.

Binding energy refers to the strength of the interaction between a biomolecule and its ligand. The dissociation constant of the enzyme-inhibitor combination is represented by the  $K_i$  value, also known as the inhibition constant. A decreased chance of dissociation is indicated by a lesser  $K_i$  value, which, in turn, leads to stronger inhibition [38]. As mentioned in Table 4, the best binding energy was demonstrated by compound **12**, followed by compound **4** and compound **1**, with values of -12.06, -11.10, and -10.76 kcal/mol, respectively, better than tamoxifen and curcumin as existing drug and lead compound. They showed interactions with important residues with the Asp351. The interactions and the conformation are presented in Table 4.

Compound **12** demonstrated the highest binding energy than other curcumin analogs. It has substituent -Br in R2 and R4 and -OH in R3. The key residue, Asp351, interacted with the side aromatic structure in compound **12** with the  $\pi$ -anion type of interaction.  $\pi$ -Anion interaction is one non-covalent interaction that can build between a negatively charged species (anion) and the electron-deficient  $\pi$  system of an aromatic ring [39]. In addition, its bonding energy is supported by several other interactions, such as halogen interaction and  $\pi$ -alkyl interactions. The  $\pi$ -alkyl interaction is an interaction that occurs in a hydrophobic environment where aromatics and

alkyl sides can interact (part of the van der Waals interaction) [40]. Compound **12** was found to be a complex compound as it demonstrated poor pharmacokinetics profiles, based on Lipinski's rule of five. However, some research works have indicated that formulations can improve the bioavailability or pharmacokinetics profile of drugs, like nanosuspensions, solid lipid nanoparticles, liposomes, or microemulsions [41].

In compound **4** and compound **1**, with -Cl substituents in R1 and R3 (compound **4**) and -Br in R2 and -OCH<sub>3</sub> in R3 (compound **1**), Asp351 residues interacted with aromatic structures forming  $\pi$ -anion interaction, similar to compound **12**. While compound **11F** acted as a native ligand, Asp321 interacted with the H group in the cyclohexanone to form a salt bridge interaction. Salt bridges are ionic interactions between oppositely charged groups. Salt bridges tend to be stronger than  $\pi$ -alkyl interactions [40]. Other interactions that occurred between compound **4** and protein were van der Waals,  $\pi$ -anion,  $\pi$ -sulfur,  $\pi$ - $\pi$ , and alkyl interactions. In compound **1**, there were carbon-hydrogen bonds,  $\pi$ -anion,  $\pi$ -sulfur,  $\pi$ - $\pi$ , and alkyl interactions that contributed to binding energy.

The curcumin analogs have higher binding energy than curcumin and tamoxifen but less than the native ligand. There is a conventional hydrogen bond in the interaction between native ligand and protein. This interaction plays a crucial role in drug binding [42], which likely explains why the native ligand exhibited a higher binding energy.

The development of artificial intelligence (AI) tools and technology has made AI-driven drug discovery more prominent. It offers speed, cost-effectiveness, and the ability to identify novel drug candidates and repurpose existing ones, whereas traditional methods like molecular docking can be computationally intensive and may struggle with large-scale screening [43]. However, we found that traditional molecular docking is better than AI-driven drug discovery, such as deep learning. This is

because some of the deep learning approaches employ an entire protein (blind docking) for docking, which does not satisfy the common requirements, whereas the old method uses the catalytic site as the binding site [44].

Many advanced deep learning techniques, such as those used for low-dose CT image denoising, could enhance the quality of this study. Improved imaging quality would enable more accurate visualization of tumor morphology and the response to curcumin-based drug candidates. Additionally, high-resolution imaging could support the identification of subtle biomarkers that are essential for understanding the mechanisms of action of medications based on curcumin and their influence on breast cancer progression. Furthermore, the integration of advanced techniques, such as attention-guided enhanced U-Net architectures, offers the opportunity to develop robust predictive models that combine imaging data with molecular and pharmacological information, facilitating a more comprehensive and data-driven approach to drug development [45, 46].

## CONCLUSION

This study is a computational study that aims to explore dibenzylidene-cyclohexanone curcumin analogs as anticancer agents for the treatment of breast cancer. It analyzed drug similarity based on Lipinski's rule of five using ADMETlab 3.0 (virtual screening), then explored structural similarity based on pharmacophore modeling using LigandScout, and finally determined how the curcumin analogs interact with hER $\alpha$  receptor based on molecular docking. The virtual screening revealed that all of the curcumin analog compounds met the criteria of Lipinski's rule of five, except **12** because it has a LogP of more than 5 and a molecular weight of more than 500 Da. Pharmacophore modeling results showed that compounds **4** and **11** have similar structures to compounds that have activity as hER $\alpha$  inhibitors (training compounds) with high pharmacophore fit-score, while molecular docking results revealed that curcumin analog compounds **12**, **4**, and **1** have better binding energy values (-12.06, -11.10, and -10.76 kcal/mol, respectively) than curcumin (-9.18 kcal/mol) and tamoxifen (-10.45 kcal/mol), one of the anticancer drugs. Research on curcumin analogs as potential inhibitors of breast cancer proteins warrants further investigation. Future studies are expected to include molecular dynamics simulations, as well as *in vitro* and *in vivo* experiments, to thoroughly evaluate the potential and mechanisms of these curcumin analog compounds.

## AUTHORS' CONTRIBUTIONS

R.: Study conceptual design R.K.H.: writing-original draft preparation.

## LIST OF ABBREVIATIONS

ADMET = Absorption, Distribution, Metabolism,  
Excretion, and Toxicology  
AUC = Areas Under the Curves

BE = Binding Energy  
EF = Enrichment Factors  
HBA = Hydrogen Bond Acceptors  
HBD = Hydrogen Bond Donors  
HBD = Hydrogen Bond Donors

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

## HUMAN AND ANIMAL RIGHTS

Not applicable.

## CONSENT FOR PUBLICATION

Not applicable.

## AVAILABILITY OF DATA AND MATERIALS

All the data and supporting information are provided within the article.

## FUNDING

This work was supported by the Directorate General of Higher Education, Research, and Technology, Ministry of Education, Culture, Research, and Technology, Indonesia, through the Pendidikan Magister menuju Doktor untuk Sarjana Unggul (PMDSU) (<https://www.pmdsu.id/>) research scheme with grant no. 048/E5/PG.02.00.PL/2024 and contract no. 2790/UN1/DITLIT/PT.01.03/2024. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

## ACKNOWLEDGEMENTS

The authors would like to express their gratitude to the Department of Medicinal Chemistry and Analysis, Faculty of Pharmacy, Padjadjaran University, especially Prof. Apt. Muchtaridi, Ph.D., for generously lending the computer and license for pharmacophore modeling (LigandScout). The contributions have enhanced the quality of this research. The authors would also like to acknowledge the bioinformatics tools, software, and databases (ADMETlab 3.0, MarvinSketch, ChemDraw, Autodock v4.2.6) utilized in this work.

## REFERENCES

- [1] World Health Organization. Breast cancer. 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- [2] Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Breast Cancer. Brisbane, Australia: Exon citations 2022.
- [3] Mohanty SS, Sahoo CR, Padhy RN. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update. Genes Dis 2022; 9(3): 648-58. <http://dx.doi.org/10.1016/j.gendis.2020.12.005> PMID: 35782984

- [4] Biason-Lauber A, Lang-Muritano M. Estrogens: Two nuclear receptors, multiple possibilities. *Mol Cell Endocrinol* 2022; 554: 111710. <http://dx.doi.org/10.1016/j.mce.2022.111710> PMID: 35787463
- [5] Huai Z, Li Z, Xue W, *et al.* Novel curcumin derivatives N17 exert anti-cancer effects through the CSNK1G3/AKT axis in triple-negative breast cancer. *Biochem Pharmacol* 2024; 229: 116472. <http://dx.doi.org/10.1016/j.bcp.2024.116472> PMID: 39127154
- [6] Praseetha NG, Divya UK, Nair S. Identifying the potential role of curcumin analogues as anti-breast cancer agents: An *in silico* approach. *Egypt J Med Hum Genet* 2022; 23(1): 100. <http://dx.doi.org/10.1186/s43042-022-00312-x>
- [7] Yin Y, Tan Y, Wei X, *et al.* Recent advances of curcumin derivatives in breast cancer. *Chem Biodivers* 2022; 19(10): e202200485. <http://dx.doi.org/10.1002/cbdv.202200485> PMID: 36069208
- [8] Yuvashri R, Thendral ED, Jonathan DR, *et al.* Evaluating a series of new curcumin derivatives as potential anti-breast cancer agents: A collective analysis of *in-vitro* and *in-silico* characterization. *Chemical Physics Impact* 2024; 9: 100663. <http://dx.doi.org/10.1016/j.chphi.2024.100663>
- [9] Dallavalle S, Dobričić V, Lazzarato L, *et al.* Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. *Drug Resist Updat* 2020; 50: 100682. <http://dx.doi.org/10.1016/j.drup.2020.100682> PMID: 32087558
- [10] Ding Y, Xue X. Medicinal chemistry strategies for the modification of bioactive natural products. *Molecules* 2024; 29(3): 689. <http://dx.doi.org/10.3390/molecules29030689> PMID: 38338433
- [11] Cheng Y, Zhong C, Yan S, Chen C, Gao X. Structure modification: A successful tool for prodrug design. *Future Med Chem* 2023; 15(4): 379-93. <http://dx.doi.org/10.4155/fmc-2022-0309> PMID: 36946236
- [12] Pourbagher-Shahri AM, Farkhondeh T, Ashrafizadeh M, Talebi M, Samargandian S. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades. *Biomed Pharmacother* 2021; 136: 111214. <http://dx.doi.org/10.1016/j.biopha.2020.111214> PMID: 33450488
- [13] Tshiyoyo KS, Bester MJ, Serem JC, Apostolides Z. *In-silico* reverse docking and *in-vitro* studies identified curcumin, 18 $\alpha$ -glycyrrhetic acid, rosmarinic acid, and quercetin as inhibitors of  $\alpha$ -glucosidase and pancreatic  $\alpha$ -amylase and lipid accumulation in HepG2 cells, important type 2 diabetes targets. *J Mol Struct* 2022; 1266: 133492. <http://dx.doi.org/10.1016/j.molstruc.2022.133492>
- [14] Zhu J, Li Q, Wu Z, Xu Y, Jiang R. Curcumin for treating breast cancer: A review of molecular mechanisms, combinations with anticancer drugs, and nanosystems. *Pharmaceutics* 2024; 16(1): 79. <http://dx.doi.org/10.3390/pharmaceutics16010079> PMID: 38258090
- [15] Wang Y, Yu J, Cui R, Lin J, Ding X. Curcumin in treating breast cancer: A review. *SLAS Technol* 2016; 21(6): 723-31. <http://dx.doi.org/10.1177/2211068216655524> PMID: 27325106
- [16] Panda SS, Girgis AS, Thomas SJ, *et al.* Synthesis, pharmacological profile and 2D-QSAR studies of curcumin-amino acid conjugates as potential drug candidates. *Eur J Med Chem* 2020; 196: 112293. <http://dx.doi.org/10.1016/j.ejmech.2020.112293> PMID: 32311607
- [17] Zamrus SNH, Akhtar MN, Yeap SK, *et al.* Design, synthesis and cytotoxic effects of curcuminoids on HeLa, K562, MCF-7 and MDA-MB-231 cancer cell lines. *Chem Cent J* 2018; 12(1): 31. <http://dx.doi.org/10.1186/s13065-018-0398-1> PMID: 29556774
- [18] Ritmaleni R, Fatmayanti RB, Ekananda SD, Tranggono BN, Arsani NK, Rumiayati R. Synthesis and antioxidant activity of some dibenzylidene-cyclohexanones. *Indones J Pharm* 2023; 34(1) <http://dx.doi.org/10.22146/ijp.4537>
- [19] Hastutitama ANA, Persitamaia I, Restiwardani I. Synthesis and antibacterial activity of dibenzylidene-cyclohexanone. *Rasayan J Chem* 2021; 14(3): 2090. <http://dx.doi.org/10.31788/RJC.2021.1436240>
- [20] Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. *Pharmacol Res* 2019; 144: 19-50. <http://dx.doi.org/10.1016/j.phrs.2019.03.006> PMID: 30877063
- [21] Fu L, Shi S, Yi J, *et al.* ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. *Nucleic Acids Res* 2024; 52(W1): W422-31. <http://dx.doi.org/10.1093/nar/gkae236> PMID: 38572755
- [22] Vuorinen A, Schuster D. Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. *Methods* 2015; 71: 113-34. <http://dx.doi.org/10.1016/j.ymeth.2014.10.013> PMID: 25461773
- [23] Moussa N, Hassan A, Gharaghani S. Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors. *Heliyon* 2021; 7(4): e06605. <http://dx.doi.org/10.1016/j.heliyon.2021.e06605> PMID: 33889764
- [24] Luo L, Zhong A, Wang Q, Zheng T. Structure-based pharmacophore modeling, virtual screening, molecular docking, ADMET, and Molecular Dynamics (MD) simulation of potential inhibitors of PD-L1 from the library of marine natural products. *Mar Drugs* 2021; 20(1): 29. <http://dx.doi.org/10.3390/md20010029> PMID: 35049884
- [25] Dykstra KD, Guo L, Birzin ET, *et al.* Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ER $\alpha$ . *Bioorg Med Chem Lett* 2007; 17(8): 2322-8. <http://dx.doi.org/10.1016/j.bmcl.2007.01.054> PMID: 17289385
- [26] Kim S, Chen J, Cheng T, *et al.* PubChem in 2021: New data content and improved web interfaces. *Nucleic Acids Res* 2021; 49(D1): D1388-95. <http://dx.doi.org/10.1093/nar/gkaa971> PMID: 33151290
- [27] Arifuzzaman S, Labu ZK, Rashid MH-O, *et al.* Identification of novel compounds targeting the liver X Receptor (LXR): *In-silico* studies, screening, molecular docking, and chemico-pharmacokinetic analysis. *Biomed Pharmacol J* 2024; 17(3): 1499-522. <http://dx.doi.org/10.13005/bpj/2960>
- [28] Wang L, Weng Z, Liang Y, Wang Y, Zhang Z, Di R. Design and implementation of parallel Lamarckian genetic algorithm for automated docking of molecules. 10th IEEE International Conference on High Performance Computing and Communications. Dalian, China, 2008, pp. 689-694. <http://dx.doi.org/10.1109/HPCC.2008.50>
- [29] Hecht F, Zocchi M, Alimohammadi F, Harris IS. Regulation of antioxidants in cancer. *Mol Cell* 2024; 84(1): 23-33. <http://dx.doi.org/10.1016/j.molcel.2023.11.001> PMID: 38029751
- [30] Pan SY, Zhou J, Gibbons L. Antioxidants and breast cancer risk: A population-based case-control study in Canada. *BMC Cancer* 2011; 11: 372. <http://dx.doi.org/10.1186/1471-2407-11-372>
- [31] Saayman M, Kannigadu C, Aucamp J, *et al.* Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines. *RSC Med Chem* 2023; 14(10): 2012-29. <http://dx.doi.org/10.1039/D3MD00220A> PMID: 37859713
- [32] Rajagopal K, Kalusalingam A, Bharathidasan AR, *et al.* *In silico* drug design of anti-breast cancer agents. *Molecules* 2023; 28(1): 4175. <http://dx.doi.org/10.3390/molecules28104175>
- [33] Aulifa DL, Amirah SR, Rahayu D, Megantara S, Muchtaridi M. Pharmacophore modeling and binding affinity of secondary metabolites from *Angelica keiskei* to HMG Co-A reductase. *Molecules* 2024; 29(13): 2983. <http://dx.doi.org/10.3390/molecules29132983> PMID: 38998937
- [34] Saravanan V, Chagaleti BK, Packiapalavesam SD, Kathiravan M. Ligand based pharmacophore modelling and integrated computational approaches in the quest for small molecule inhibitors against hCA IX. *RSC Advances* 2024; 14(5): 3346-58. <http://dx.doi.org/10.1039/D3RA08618F> PMID: 38259989
- [35] Agu PC, Afukwa CA, Orji OU, *et al.* Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. *Sci Rep* 2023; 13(1): 13398.

- <http://dx.doi.org/10.1038/s41598-023-40160-2> PMID: 37592012
- [36] Ramirez D, Caballero J. Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? *Molecules* 2018; 23(5): 1038. <http://dx.doi.org/10.3390/molecules23051038> PMID: 29710787
- [37] Farrar M, Jacob T. Tamoxifen. Treasure Island, FL: StatPearls Publishing 2023.
- [38] Pandey AK, Verma S. An *in-silico* evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease. *J Biomol Struct Dyn* 2022; 40(1): 136-42. <http://dx.doi.org/10.1080/07391102.2020.1809522> PMID: 32811367
- [39] Wang D-X. Application of anion- $\pi$  interaction on supramolecular self-assembly. In: Liu Y, Chen Y, Zhang H-Y, Eds. *Handbook of Macrocyclic Supramolecular Assembly*. Assem, Singapore: Springer 2019; pp. 1-23. [http://dx.doi.org/10.1007/978-981-13-1744-6\\_11-1](http://dx.doi.org/10.1007/978-981-13-1744-6_11-1)
- [40] Jian MQ, Xie HH, Xia KL, Zhang YY. Challenge and opportunities of carbon nanotubes. *Industrial Applications of Carbon Nanotubes: Micro and Nano Technologies*. Elsevier 2017; pp. 433-76. <http://dx.doi.org/10.1016/B978-0-323-41481-4.00015-0>
- [41] Sahu RK, Khan J. Formulation strategies to improve the bioavailability of poorly absorbed drugs. *Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery Strategies*. Elsevier 2021; pp. 229-42. <http://dx.doi.org/10.1016/B978-0-12-820043-8.00009-8>
- [42] Triptow J, Meijer G, Fielicke A, Dopfer O, Green M. Comparison of Conventional and nonconventional hydrogen bond donors in Au<sup>+</sup> complexes. *J Phys Chem A* 2022; 126(24): 3880-92. <http://dx.doi.org/10.1021/acs.jpca.2c02725> PMID: 35687835
- [43] Chakraborty C, Bhattacharya M, Lee SS, Wen ZH, Lo YH. The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges. *Mol Ther Nucleic Acids* 2024; 35(3): 102295. <http://dx.doi.org/10.1016/j.omtn.2024.102295> PMID: 39257717
- [44] Yu Y, Lu S, Gao Z, Zheng H, Ke G. Do deep learning models really outperform traditional approaches in molecular docking? *Arxiv* 2023. <http://dx.doi.org/10.48550/ARXIV.2302.07134>
- [45] Zubair M, Md Rais H, Alazemi T. A novel attention-guided enhanced u-net with hybrid edge-preserving structural loss for low-dose CT image denoising. *IEEE Access* 2024; 13: 6909-23. <http://dx.doi.org/10.1109/ACCESS.2025.3526619>
- [46] Zubair M, Md Rais HB, Ullah F, Al-Tashi Q, Faheem M, Ahmad Khan A. Enabling predication of the deep learning algorithms for low-dose CT scan image denoising models: A systematic literature review. *IEEE Access* 12: 79025-50. <http://dx.doi.org/10.1109/ACCESS.2024.3407774>